Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,330,767

« Back to Dashboard

Summary for Patent: 5,330,767

Title: Sustained release microcapsule
Abstract:Microcapsules are advantageously produced with high take-up of a water-soluble drug by preparing a W/O emulsion composed of a water-soluble drug-containing solution as the inner aqueous phase and a polymer-containing solution as the oil phase, dispersing said emulsion in an aqueous phase and subjecting the resulting W/O/W emulsion to an in-water drying, wherein the viscosity of the W/O emulsion used in preparing the W/O/W emulsion is adjusted to about 150 to about 10,000 centipoises.
Inventor(s): Yamamoto; Masaki (Osaka, JP), Takada; Shigeyuki (Osaka, JP), Ogawa; Yasuaki (Osaka, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:07/936,726
Patent Claim Types:
see list of patent claims
Dosage form; Process;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,330,767

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan60-22978Feb 07, 1985
Japan60-267977Nov 27, 1985

International Patent Family for Patent: 5,330,767

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary196702► Subscribe
European Patent Office0190833► Subscribe
Spain551696► Subscribe
Spain8703739► Subscribe
Greece860332► Subscribe
Hong Kong137793► Subscribe
HungaryT45893► Subscribe
Ireland860199► Subscribe
Germany3678308► Subscribe
Canada1260395► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
US Department of Justice
Chinese Patent Office
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: